芦可替尼治疗后隐匿性乙型肝炎感染再激活 - Suppr

Suppr

超能文献

Occult hepatitis B infection reactivation after ruxolitinib therapy.

作者信息

Perricone Giovanni, Vinci Maria, Pungolino Ester

机构信息

Hepatology and Gastronterology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

出版信息

Dig Liver Dis. 2017 Jun;49(6):719. doi: 10.1016/j.dld.2017.03.004. Epub 2017 Mar 18.

DOI:10.1016/j.dld.2017.03.004

PMID:28410914

Abstract

摘要

相似文献

Occult hepatitis B infection reactivation after ruxolitinib therapy.

Dig Liver Dis. 2017 Jun;49(6):719. doi: 10.1016/j.dld.2017.03.004. Epub 2017 Mar 18.

Hepatitis B virus reactivation associated with ruxolitinib.

Ann Hematol. 2014 Jun;93(6):1075-6. doi: 10.1007/s00277-013-1936-5. Epub 2013 Oct 31.

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

Cancer Med. 2019 Jun;8(6):2802-2809. doi: 10.1002/cam4.2147. Epub 2019 Apr 17.

Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14.

Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.

Am J Gastroenterol. 2016 Dec;111(12):1854-1856. doi: 10.1038/ajg.2016.422.

Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.

Am J Hematol. 2014 Mar;89(3):344-6. doi: 10.1002/ajh.23637.

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646.

Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.

Intern Med. 2016;55(10):1341-4. doi: 10.2169/internalmedicine.55.5529. Epub 2016 May 15.

Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.

In Vivo. 2019 Sep-Oct;33(5):1667-1669. doi: 10.21873/invivo.11653.

Imatinib and ruxolitinib association: first experience in two patients.

Haematologica. 2014 Jun;99(6):e76-7. doi: 10.3324/haematol.2013.102525. Epub 2014 Mar 14.

引用本文的文献

Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.

World J Hepatol. 2023 Nov 27;15(11):1188-1195. doi: 10.4254/wjh.v15.i11.1188.

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.

Front Immunol. 2021 Nov 19;12:750346. doi: 10.3389/fimmu.2021.750346. eCollection 2021.

Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.

Cancers (Basel). 2020 Oct 26;12(11):3132. doi: 10.3390/cancers12113132.

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.

Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20.

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?

RMD Open. 2020 Feb;6(1). doi: 10.1136/rmdopen-2020-001171.

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Leukemia. 2019 Apr;33(4):844-862. doi: 10.1038/s41375-019-0388-x. Epub 2019 Jan 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Occult hepatitis B infection reactivation after ruxolitinib therapy.

作者信息

Perricone Giovanni, Vinci Maria, Pungolino Ester

机构信息

Hepatology and Gastronterology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

出版信息

Dig Liver Dis. 2017 Jun;49(6):719. doi: 10.1016/j.dld.2017.03.004. Epub 2017 Mar 18.

DOI:10.1016/j.dld.2017.03.004

PMID:28410914

Abstract

摘要

相似文献

Occult hepatitis B infection reactivation after ruxolitinib therapy.

Dig Liver Dis. 2017 Jun;49(6):719. doi: 10.1016/j.dld.2017.03.004. Epub 2017 Mar 18.

Hepatitis B virus reactivation associated with ruxolitinib.

Ann Hematol. 2014 Jun;93(6):1075-6. doi: 10.1007/s00277-013-1936-5. Epub 2013 Oct 31.

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

Cancer Med. 2019 Jun;8(6):2802-2809. doi: 10.1002/cam4.2147. Epub 2019 Apr 17.

Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14.

Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.

Am J Gastroenterol. 2016 Dec;111(12):1854-1856. doi: 10.1038/ajg.2016.422.

Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.

Am J Hematol. 2014 Mar;89(3):344-6. doi: 10.1002/ajh.23637.

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646.

Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.

Intern Med. 2016;55(10):1341-4. doi: 10.2169/internalmedicine.55.5529. Epub 2016 May 15.

Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.

In Vivo. 2019 Sep-Oct;33(5):1667-1669. doi: 10.21873/invivo.11653.

Imatinib and ruxolitinib association: first experience in two patients.

Haematologica. 2014 Jun;99(6):e76-7. doi: 10.3324/haematol.2013.102525. Epub 2014 Mar 14.

引用本文的文献

Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.

World J Hepatol. 2023 Nov 27;15(11):1188-1195. doi: 10.4254/wjh.v15.i11.1188.

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.

Front Immunol. 2021 Nov 19;12:750346. doi: 10.3389/fimmu.2021.750346. eCollection 2021.

Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.

Cancers (Basel). 2020 Oct 26;12(11):3132. doi: 10.3390/cancers12113132.

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.

Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20.

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?

RMD Open. 2020 Feb;6(1). doi: 10.1136/rmdopen-2020-001171.

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Leukemia. 2019 Apr;33(4):844-862. doi: 10.1038/s41375-019-0388-x. Epub 2019 Jan 30.